Skip to main content

Advertisement

Table 3 Univariate survival analysis of prognostic factors of NSCLC (n = 42)

From: Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer

Variables n Median survival (95% CI) (days) P
Age (years)    
   <60 27 370.0 (301.3-438.7) 0.665
   ≥ 60 15 333.0 (244.6-421.4)  
Stage    
   III 23 416.0 (369.1-462.8) 0.163
   IV 19 327. 0 (298.7-355.3)  
T factor    
   T2-T3 17 431.0 (315.3-546.7) 0.051
   T4 25 348.0 (248.3-447.6)  
N factor    
   N0-N1 21 394.0 (312.2-475.8) 0.380
   N2-N3 21 348.0 (310.1-385.9)  
ECOG    
   1 30 403.0 (327.9-478.0) 0.130
   2-3 12 333.0 (311.5-354.5)  
Histology    
   SCC 31 367.0 (288.1-445.9) 0.270
   ADC 11 394.0 (324.8-463.1)  
Smoking habit    
   Smokers 36 370.0 (294.0-446.0) 0.745
   Non-smokers 06 367.0 (248.7-485.3)  
Tobacco habit    
   Yes 08 394.0 (352.3-435.6) 0.022
   No 34 314.0 (266.0-362.0)  
Plasma VEGF (median)    
   <275.2 pg/mL 21 348.0 (246.1-449.9) 0.885
   ≥ 275.2 pg/mL 21 370.0 (288.3-451.7)  
  1. T, tumor; N, nodal status; ECOG, Eastern Cooperative Oncology Group; VEGF, vascular endothelial growth factor; 95% CI, 95% confidence interval.